LEO Pharma

Globally known professor and dermatologist joins LEO Pharma

Del

Ahead of EADV, LEO Pharma announces that Professor Alexander Egeberg, a board-certified dermatologist, and top key opinion leader, will join the company as Head of Global Medical Affairs.

GLOBAL RELEASE – NOT FOR UK USE – NOT INTENDED FOR UK MEDIA

BALLERUP, Denmark, October 9, 2023 – LEO Pharma A/S, a global leader in medical dermatology, is today announcing the appointment of Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new Vice President, Head of Global Medical Affairs. The announcement happens ahead of the upcoming 32nd European Academy of Dermatology and Venereology (EADV) Congress.  

Alexander Egeberg joins LEO Pharma from a role as Professor of Dermatology at the University of Copenhagen and head of one of the largest clinics in Northern Europe for biologic therapy at Bispebjerg Hospital's Department of Dermatology.  He is a globally known professor and a board-certified dermatologist with an extensive research and clinical background. Having authored over 300 international scientific publications, he is an expert in inflammatory skin diseases with extensive experience in epidemiology, real-world evidence, translational medicine, and clinical trials. In addition Alexander has through his work in Medial Affairs at Pfizer and as a consultant for additional global pharma companies built a solid understanding of corporate pharma. The appointment of Professor Egeberg cements LEO Pharma’s commitment to medical dermatology and to integrate the clinicians and patients voices at the core of the organization.

Professor Alexander Egeberg comments:  

“I am genuinely excited to join LEO Pharma as Vice President, Head of Global Medical Affairs. Medical dermatology is a rapidly evolving field, yet there are still many diseases with few or no good treatment options. LEO Pharma has a proud 115-year legacy in dermatology, but their ambition and transformative journey is beyond exhilarating. I look very much forward to applying my experience and perspective to support the company’s commitment to advancing care for patients with dermatological diseases.”

Becki Morison, EVP Global Product Strategy and International Operations with LEO Pharma comments:  
 
“I am very pleased that such a strong, international profile in the dermatology space has decided to join LEO Pharma. With him on board we are adding extensive clinical experience and strong understanding of patients’ needs into our medical affairs work.  Alexander will certainly strengthen a dermatologic mindset across our organization and ensure that we always put patient needs at the core as we continue to make a fundamental difference for those who need us most in medical dermatology. I am thrilled to welcoming Alexander to our team and looking forward to seeing his contributions to Global Medical Affairs and to our organization.” 

Professor Egeberg will start in his new role January 1, 2024, reporting to Becki Morison. He will remain affiliated with the Department of Dermatology at Bispebjerg Hospital, and the University of Copenhagen to ensure that the patients’ needs, and the voice of the medical community remains deeply embedded in the core values and practices of the company going forward. 

Kontakter

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,400 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.

Følg pressemeddelelser fra LEO Pharma

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra LEO Pharma

LEO Pharma to present at the 44th annual J.P. Morgan Healthcare Conference7.1.2026 13:00:00 CET | Pressemeddelelse

Ballerup, Denmark, January 7, 2026 – LEO Pharma, a global leader in medical dermatology, announced today that CEO Christophe Bourdon will deliver a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 9:00 AM PST. With over 60 years of specialist expertise in medical dermatology and more than 90 million patients served in 70+ markets, LEO Pharma is uniquely positioned in one of healthcare’s most attractive and underserved sectors. Backed by an unmatched portfolio combining category‑leading brands with first‑in‑class innovations, the company is redefining standards of care for patients with high unmet needs. Entering 2026, LEO Pharma builds on the strong momentum of recent years, marked by robust top-line growth, significant margin expansion, and a promising pipeline. Leveraging its unique global platform, the LEO Pharma is advancing innovation as the preferred partner in medical dermatology. The J.P. Morgan Healthcare Con

LEO Pharma submits adolescent label expansion application for Anzupgo® to EMA15.12.2025 09:00:00 CET | Pressemeddelelse

LEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).1 The label expansion submission for adolescent patients demonstrates LEO Pharma's commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.

LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial17.11.2025 09:00:00 CET | Pressemeddelelse

The ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.

LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook6.11.2025 09:00:00 CET | Pressemeddelelse

Ballerup, Denmark, 6 November, 2025 - In the first nine months of 2025, LEO Pharma continued its robust revenue growth, with significantly improved profitability and free cash flow. As expected, growth accelerated in the third quarter, with the global rollout of Anzupgo® gaining further momentum after its September launch in the U.S. The 2025 financial outlook is updated to reflect the addition of Spevigo® to the portfolio, reinforcing LEO Pharma’s commitment to advancing innovation and expanding access to care. Highlights LEO Pharma’s revenue increased by 7% to DKK 10,064 million, and by 8% at constant exchange rates (CER), entirely driven by organic growth. The revenue growth was led by North America (+27% at CER), with Europe (+2% at CER) and Rest of World (+6% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 9% (CER), driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 41% (CER), in ad

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye